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Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant 
brain tumor. Despite the efforts developed in the respective treatment, consisting of 
maximal surgical resection followed by adjuvant radiotherapy and chemotherapy, the 
prognosis remains very poor. This may be partly related to the resistance of GBM cells 
and their infiltrative and invasive nature into the surrounding brain tissue. Therefore, 
newer and challenging alternative approaches for the treatment have emerged, including 
immunotherapy. This anticancer therapy, based on the stimulation of the host’s immune 
system, has been currently investigated and several advances in the clinical trial stage 
have already been reached. Immunotherapeutic strategies comprise a set of modalities, 
including vaccines (cell-free and cell-based), chimeric antigen receptor (CAR) T-cell 
therapy, immune checkpoint inhibitors, monoclonal antibodies (mAbs), and oncolytic 
viruses (OVs). In this chapter, we will review the principal concepts and the recent prog-
ress in immunotherapy for GBM.
Keywords: glioblastoma multiforme, immunotherapy, vaccine, antigen, dendritic cell, 
clinical trial
1. Introduction
Glioblastoma multiforme (GBM), histologically a World Health Organization (WHO) grade 
IV glioma, is the most common and aggressive malignant brain tumor, accounting for 
approximately 45–50% of all primary malignant brain tumors. Despite the efforts developed 
by its current standard therapy (maximal surgical tumor resection followed by concomitant 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
radiotherapy plus temozolomide (TMZ) chemotherapy), GBM remains an incurable disease 
with a poor prognosis that attains a median survival of 14.6 months and a mean survival rate 
of 0.05–4.7% at 5 years, which is partially due to its heterogeneous and invasive nature as well 
as to the tumor resistance [1–3]. In addition, it is well-known that the protective nature of 
the blood–brain barrier (BBB) limits the entry of therapeutic agents into the brain and conse-
quently hampers the success of therapies [4].
Recently, new and promising immunotherapeutic approaches have emerged and evidenced a 
great impact in GBM treatment, harnessing the ability of the host’s immune system to induce 
or enhance antitumor responses [2, 5]. These immunotherapeutic strategies are related with 
both active immunotherapy, such as vaccines (cell-free and cell-based), and passive immu-
notherapy, namely monoclonal antibodies (mAbs), immune checkpoint inhibitors, chimeric 
antigen receptor (CAR) T-cell therapy and oncolytic viruses (OVs). Despite the presence of the 
BBB, such strategies can be successful by considering some key points. If immunotherapy is 
intended to be given intravenously, the BBB is effectively a problem, but likely to be exceeded. 
On the one hand, it is noteworthy that patients with GBM tend to have a fenestrated endothe-
lium with BBB disruption, which will possibly facilitate the passage of immunotherapeutic 
cells. On the other hand, there are already mechanisms to induce a reversible BBB opening 
with a transiently increase in the respective permeability. Nonetheless, there is currently an 
easier and more effective approach, which consists of direct intracranial injection of immuno-
therapeutic agents, thus overcoming the problems associated with the BBB [4, 6].
Regardless the low number of clinical trials (CT) that are completed to date, the early results 
reached for all of these strategies are generally related with positive patient outcomes, which 
has increased the interest in proceeding with the investigations. This chapter provides a brief 
description and the currently ongoing CT of all of these therapies, with particular emphasis 
on vaccines. In fact, vaccination represents a valuable therapeutic option in cancer since it can 
induce widespread and sustained antitumor effects, with less toxicity than standard chemo-
therapy [7, 8].
2. The spectrum of vaccine strategies in glioblastoma
Contrary to chemotherapy and passive immunotherapy, vaccination does not have a direct 
antitumor effect, but rather boosts the immune system to destroy tumor cells [9]. More pre-
cisely, vaccines aim at inducing tumor-specific immune responses, mainly based on CD8+ 
cytotoxic T lymphocytes (CTL), which are specific to tumor antigens [10]. According to the 
strategy used to present the antigens to the immune system, cancer vaccines can be divided 
mainly in two groups, cell-free or cell-based vaccines [11].
2.1. Cell-free vaccines
Treatment with cell-free vaccines consists on direct inoculation of single or multi antigens, 
later presented to host antigen-presenting cell (APC) that, upon such stimulation, migrate 
to lymph nodes where they boost immune response. In this group are included a peptide, 
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multipeptide, and heat-shock protein (HSP) vaccines, whose applicability has already been 
developed for GBM [11–13].
2.1.1. Peptide and multipeptide vaccines
Cancer peptide vaccines take advantage of peptides to trigger a pharmacological activity 
through the mobilization of the immune system against tumor antigens [13]. Investigating 
the expression profile of antigens in human GBM thus becomes the most important step in the 
process of developing vaccine-directed immunotherapy [14]. In fact, multiple glioma-related 
antigens have been identified and even tested in vaccine trials over the last years, but only 
a few reached promising results given the known variable expression patterns of proteins/
antigen among GBM patients [14, 15]. These vaccines may incorporate a single or multiple, 
long or short peptides acting as tumor antigens, which are often coupled to carrier proteins in 
order to potentiate their immunogenicity [15, 16]. Although being a recent treatment modality 
in oncology, GBM has already a varied range of successfully proven vaccines, many of them 
peptide/multipeptide vaccines [11].
Considering the frequent amplification of epidermal growth factor receptor (EGFR) and its 
active mutant EGFRvIII in GBM, many researchers have focused their works on developing 
EGFRvIII vaccines with remarkable clinical results. For instance, rindopepimut (also called 
Rintega® and CDX-110) was subjected to a number of phase I/II CT since its introduction 
(VICTORI, pediatric pontine glioma pilot study (NCT01130077), ACTIVATE (NCT00643097), 
ACT II, ACT III (NCT00458601), and ReACT (NCT01498328)), where its clinical efficacy was 
clearly shown in patients with GBM. Such vaccination resulted in prolonged progression-
free and overall survival (OS) with no safety concerns. However, a phase III CT (ACT IV 
(NCT01480479)) with rindopepimut was discontinued since the study failed to meet its 
primary OS endpoint [7, 17, 18]. Another example is a live attenuated Listeria-based vaccine 
(ADU-623) expressing both EGFRvIII and NY-ESO-1 antigens, which is currently being tested 
in patients with recurrent GBM through a phase I CT (NCT01967758) [11, 18].
Despite the increased interest in EGFRvIII, other antigens have been considered for the 
investigation of immunotherapy in GBM, with emphasis on SurVaxM, PEPIDH1M, and 
DSP-7888 vaccines. SVN53-67/M57 (SurVaxM), a peptide vaccine derived from survivin, not 
only has revealed promising results in preclinical studies with GL261-bearing mice but has 
also been investigated in CT (phase II so far (NCT02455557)) [11, 18, 19]. Since isocitrate 
dehydrogenase 1 (IDH1) is an enzyme commonly mutated in GBM, it has been developed 
IDH1 peptide vaccines for patients with glioma positive for IDH1 R132H mutation (pre-
sented in 5–12% of GBMs). Currently, two phase I CT are being conducted for that purpose, 
called RESIST trial (NCT02193347) with PEPIDH1M vaccine and NOA-16 (NCT02454634), 
both of which target patients with IDH1R132H-mutated gliomas [15, 20]. Another devel-
oping peptide vaccine uses the tumor-associated antigens (TAA) Wilm’s tumor protein-1 
(WT-1), recognized as an oncogene expressed in GBM responsible for tumor growth. 
WT1 peptide vaccination has been investigated through several phases I/II CT, alone or 
in combination with other therapeutics, including TMZ. Overall, the results of these WT1-
based vaccines have been positive, confirming their safety profile along with good clinical 
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responses. By way of example, DSP-7888 vaccine revealed to induce a specific CTL and 
helper T-lymphocyte-mediated immune responses against WT1 expressing GBM, in a phase 
I CT (NCT02498665) [11, 18].
When not one but several antigens are incorporated in the same vaccine, multi-peptide vac-
cines are obtained as the case of IMA950, SL-701, and ERC-1671 vaccines. In fact, combin-
ing multiple peptides in a single mixture may offer therapeutic advantages bearing in mind 
the heterogeneous gene expression profiles in different GBM [15, 21]. IMA950 is a vaccine 
encompassing 11 peptides naturally presented in GBM tissue (brevican; chondroitin sulfate 
proteoglycan 4; fatty acid binding protein 7, brain; insulin-like growth factor 2 mRNA binding 
protein 3; neuroligin 4, X-linked; neuronal cell adhesion molecule; protein tyrosine phospha-
tase, receptor-type, Z polypeptide 1; tenascin C; Met proto-oncogene; baculoviral inhibitor 
of apoptosis protein repeat-containing 5; and hepatitis B virus core antigen). This multipep-
tide vaccine has been subjected to numerous phase I/II CT (NCT02924038, NCT01920191, 
NCT01403285, and NCT01222221), alone or combined with other therapies, whose results are 
still somewhat inconclusive as to its clinical efficacy [11, 18]. Another case, the SL-701 vaccine 
composed of 3 peptides (a highly immunogenic mutant to target survivin, interleukin-13 
receptor α-2 (IL-13Rα2), and ephrin A2) was investigated in adults with recurrent GBM 
through a phase I/II CT (NCT02078648), although the results have not yet been disclosed 
[11, 14, 18]. A slightly more complex vaccine concerns ERC-1671 (Gliovac) since it uses a 
combination of allogeneic tumor cells (derived from three different GBM donors), autolo-
gous GBM tumor cells (resultant from resected tumor of the patient) and GBM tumor lysates. 
Given the notable results obtained from the first clinical studies, this multi-peptide vaccine 
moved toward a phase II CT (NCT01903330), being examined in recurrent, bevacizumab naive 
GBM patients [11]. As it is well-known, O6-methylguanin-DNA-methyltransferase (MGMT) 
unmethylated GBM is correlated with TMZ resistance and worse prognosis of the tumor [22]. 
Such evidence led to the development of a personalized neoantigen cancer vaccine (NeoVax), 
which is currently being examined in a phase I CT (NCT03422094) along with radiotherapy 
in newly diagnosed GBM with exclusively unmethylated MGMT promoters [18].
2.1.2. Heat-shock protein (HSP) vaccines
HSPs act as chaperones for intracellular proteins, so they have the ability to bind, fold and 
chaperone an antigenic representation of the cells from which they are originated. Based on 
this fact, HSPs isolated and purified from a patient’s resected tumor can be subsequently rein-
fused, and then they will promote the presentation of antigenic peptides to APCs, which elicit 
antigen-specific CTL responses [11, 18]. Among the proteins of the HSP family, expressed in 
GBM, HSP70 and HSP90 stand out. Despite the dysregulation of these HSP families being 
reported to play a critical role in tumor proliferation, invasiveness, and metastasis, in addi-
tion to suppression of apoptosis, HSP70 and HSP90 have also shown ability to bind antigenic 
peptides, which can elicit tumor rejection responses [23]. HSP70 family inhibits cell stress-
induced apoptotic pathways, facilitates protein folding, and guides protein transport across 
membranes, while HSP90 mainly assists in protein folding, protein stabilization, and peptide 
loading onto major histocompatibility complex (MHC) class I molecules. Particularly, HSP90 
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was found to bind to EGFRvIII, FAK, AKT, hTERT, p53, cdk4, MAPK, and PI3K in GBM, 
which are involved in key tumor initiation and proliferation signaling pathways. Although 
the studies have been conducted for other types of tumors, it is believed that the same 
may occur with GBM, with HSP presenting tumor-specific antigens to stimulate antitumor 
immune responses [11, 24, 25]. Autologous tumor-derived HSP-peptide complex 96 (HSPPC-
96) have generated great interest over the last few years, reason why it has been the most used 
in HSP vaccine trials. In fact, HSPPC-96 has been extensively explored in several phases I/II 
CT (NCT02722512, NCT00905060, NCT01814813, NCT00293423, and among others), most of 
them for GBM patients, inducing strong tumor-specific immune responses with the improved 
median OS [11, 14, 18, 26].
2.2. Cell-based vaccines
Contrary to the vaccines previously presented, cell-based vaccines (as the name itself indi-
cates) first resort to APCs ex vivo, most often dendritic cells (DCs) extracted from the patient, 
loading them with tumor antigens. After activation, they are injected into the host, presenting 
the antigens to naive T cells of the adaptive immune system [11, 27].
2.2.1. Dendritic cells (DCs) vaccines
As is already known, DC are considered the optimal APC of the immune system, due to 
their ability to stimulate T and B lymphocytes, in addition to promoting natural killer (NK) 
T cells activation [28, 29]. As such, a wide range of antigen sources has been explored for 
pulsing of DC, and include tumor peptides, autologous tumor lysates, tumor-derived mRNA 
(messenger RNA), glioblastoma stem cells (GSCs) and viral antigens. All of these strategies 
have already been properly tested in GBM, proving to be immunogenic with very promising 
outcomes [5, 11, 14, 15, 28].
Referring to tumor peptide-loaded DCs, we here present the two most important so far: 
autologous DC pulsed with an EGFRvIII peptide conjugated with keyhole limpet hemocya-
nin (PEPvIII-KLH), and the ICT-107 autologous vaccine [11]. The latter concerns patient DCs 
pulsed with six synthetic TAAs (AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Rα2, 
four of which are considered GSC-associated, and whose results obtained in phase I/II CT 
(NCT01280552) are quite encouraging for the ongoing phase III CT (NCT02546102) in GBM 
[5, 11, 14]. As a matter of fact, ICT-107 is also considered a tumor stem cell vaccine. It should 
be recalled that GBM possesses a small subpopulation of self-renewing, tumorigenic GSC, 
which drive invasive tumor growth and therapeutic resistance. Among the biomarkers 
studied, CD133 has been used extensively to identify and isolate tumor stem cells, given its 
overexpression on these malignant cells [7, 18, 30]. In this sense, ICT-107 vaccine was found 
to decrease CD133+ cells from recurrent GBM; moreover, the tumor stem cell vaccine ICT-
121 consists of autologous DC pulsed with purified peptides from CD133, whose safety and 
clinical response will be assessed in a phase I CT now ongoing (NCT02049489) [18]. Still on 
the stemness, another way to take advantage of GSC is to develop tumor-derived mRNA-
loaded DCs vaccines. In this case, autologous GSC cultures are established from resected 
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tumor, followed by isolation of RNA and amplification of mRNA, then transfected into DC 
[31, 32]. As such, a phase I CT (NCT00890032) studied CD133+ autologous brain tumor stem 
cell (BTSC) mRNA-loaded DC in patients with recurrent GBM, which revealed to be safe, 
feasible and well-tolerated [32].
An alternative approach involves using tumor cell lysates-loaded DCs, such as DCVax®-L 
vaccine in which cellular fragments (derived from the patient’s own resected tumor) are 
pulsed into DCs. In fact, this technique offers the advantage of collecting a broad spec-
trum of patients’ tumor antigens, known and unknown (given the heterogeneity of antigen 
expression among gliomas), thus triggering a polyclonal immune response [11, 14, 28, 33]. 
DCVax®-L, one of the most promising vaccines for GBM, consists of an autologous DC vac-
cine that is currently under evaluation in a phase III CT (NCT00045968). Previous studies 
(phase I/II CT) have proved its safety profile, also demonstrating that vaccine can increase 
progression-free and OS in newly diagnosed GBM (2 out of 39 patients survived more than 
10 years) [2, 18, 34].
It has been reported that most GBM express exclusive human cytomegalovirus (CMV) proteins, 
as for example IE1, US28, pp65, gB, HCMV IL-10, and pp28. Such evidence made possible the 
use of immunodominant CMV antigens to produce viral antigen-loaded DCs, aimed at treating 
GBM patients [14, 15]. Exciting results were obtained in a study with patient-derived DCs pulsed 
with CMV pp65 RNA since the stimulation of CMV pp65-specific cytotoxic T cells resulted in 
recognition and destruction of autologous GBM tumor cells in an antigen-specific manner [35]. 
In the wake of this outcome, a phase II CT (NCT02366728) is currently ongoing testing the CMV 
pp65 RNA-pulsed autologous DC vaccine along with tetanus/diphtheria toxoid helper vaccine, 
for newly diagnosed GBM patients [18]. In addition, the DC vaccine PEP-CMV comprises two 
peptides, derived from human pp65 and gB, and has been investigated in some phase I CTs 
(NCT01854099, NCT02864368, and NCT03299309) without published results so far [7, 15].
2.2.2. Human umbilical vein endothelial cell (HUVEC) vaccines
Less commonly used in vaccines, but also with ongoing trials for GBM, are the glutaralde-
hyde-fixed human umbilical vein endothelial cells (HUVECs). [14, 36]. As it is well known, 
angiogenesis is a hallmark of GBM that facilitates tumor progression and invasiveness. Based 
on that, HUVEC vaccination consists of an endovascular targeting immunotherapy intended 
to trigger an antiangiogenic response, upon presentation of HUVEC antigen to the immune 
system [14, 37]. To the best of our knowledge, only two preliminary CT was conducted 
with HUVEC vaccines for recurrent GBM patients, whose clinical outcomes were promis-
ing without serious adverse events associated [14, 36, 38]. In addition, an interesting in vivo 
study assessed the effect of a combined vaccine, prepared from GBM and endothelial cells, 
on glioma-bearing mice. While tumor growth inhibition was seen only in the preventive use 
of the combined vaccine, a significantly decrease in vessel account was verified in the tumor 
upon the therapeutic experiment with that vaccine [37].
2.2.3. Autologous formalin-fixed tumor vaccines (AFTVs)
Last but not least, are whole tumor cell vaccines, which use autologous formalin-fixed tumor frag-
ments obtained from surgical removal to trigger in vivo antigen-specific CTL responses [39, 40]. 
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Actually, formalin fixation technique has been used since it allows admirable preservation of 
tissue morphology, and consequently, the antigenicity of tumor cells [14, 40]. A CT with an 
autologous formalin-fixed tumor vaccine (AFTV) being tested in 12 primary GBM patients 
demonstrated the safety and viability of the vaccine, along with promising clinical responses 
that were also achieved [40]. Another study, phase I/IIa CT, examined the impact of an AFTV 
concomitant with radiotherapy in 22 resected patients with newly diagnosed GBM. Such 
trial resulted in median OS of 19.8 months with an actuarial 2-year survival rate of 40%, 
in addition to not reporting serious adverse events [39]. Interestingly, an immunotherapy 
strategy combining cellular vaccines (prepared from autologous GL261 murine glioma cells 
and F-2 murine endothelial cells) was tested on glioma-bearing mice. Such preclinical study 
revealed that combined vaccine significantly decreased tumor growth and vessel account, 
thus representing an expecting strategy capable to target both GBM cells and their microen-
vironment [37].
2.3. Advantages and disadvantages of cell-free and cell-based vaccines
Throughout this chapter, several candidate vaccine approaches are presented for GBM treat-
ment. Although most of them have demonstrated safety and clinical benefit in different 
Strategy Advantages Disadvantages
Cell-free 
vaccines
• Easy to synthethize, purify, produce and 
standardize; [16, 41, 42]
• Cost-effective approach; [41]
• Safe with no biological contamination  
(in case of synthetic peptides); [42]
• Stable in storage; [16]
• Possibility of selecting one or more 
antigens (stimulation of an specific immune 
response); [16, 41]
• Fully-defined composition;
• Low risk of allergic and auto imune 
responses, as well as of oncogenicity effects 
[41, 42]
• Prior and proper identification of immunogenic 
epitope(s); [41]
• Existence of antigen-loss tumor variants; [16]
• MHC restriction; [41]
• Lack of helper activity and weak presentation 
of antigen by endogenous APC (contrary to the 
cross-presentation by DC); [16]
• Instability of peptides in vivo being rapidly 
degraded by peptidases [16]
Cell-based 
vaccines
• Bypass the endogenous DC dysfunction in 
cancer patients; [43]
• Cross-presentation of exogenous antigens 
by DC; [44]
• Great ability of DC to prime T cells to attack 
the tumor; [44]
• AFTV provide the entire spectrum of TAAs 
with no need to select the most proper 
antigen to target the tumor; [45]
• Safe, multivalent and patient-specific [12]
• High production costs; [42]
• Quality concerns due to the manufacture highly 
variable; [12, 42]
• Poor immunogenicity of the tumor cell them-
selves; [12]
• Most of them are restricted to patients with a 
resectable tumor; [42, 46]
• Some failure rate associated with culture of 
autologous tumor cells [46]
MHC: major histocompatibility complex; APC: antigen-presenting cell; DC: dendritic cell; TAA: tumor-associated 
antigens; AFTV: autologous formalin-fixed tumor vaccine.
Table 1. Overall assessment of cell-free and cell-based vaccines.
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preclinical and clinical studies, it is essential to understand some intrinsic advantages and 
disadvantages of cell-free and cell-based vaccines in cancer therapy (Table 1).
3. Other immunotherapeutic strategies
Equally important, immunotherapeutic approaches, such as monoclonal antibodies, immune 
checkpoint inhibitors, adoptive T-cell therapy, CAR T-cell therapy and oncolytic viruses, have 
been investigated in the treatment of GBM [47]. Some related clinical data are presented in 
Table 2, with an indication of the CT ID.
3.1. Monoclonal antibodies (mAbs)
One of the most intensively explored passive immunotherapeutic approach resorts to mAbs. 
These are able to recognize cell surface receptors and ligands, which provide a successful 
strategy to target antigens highly expressed in tumor cells or receptors involved in tumori-
genesis [6]. They can function through a set of ways, such as by blocking ligand-receptor 
binding and/or downstream signaling pathways, targeting the tumor microenvironment, 
immune cells or immunosuppressive tumor microenvironments, and modulating constant 
fragment (Fc) domain of antibodies [48].
The mAbs have been applied as immunotherapeutic agents in GBM treatment. Two tar-
gets expressed on GBM cells are vascular endothelial growth factor (VEGF) and EGFR 
or its variant III mutation EGFRvIII. Bevacizumab, a humanized antibody against VEGF, 
was the first mAb studied in the treatment of GBM patients. This mAb has the ability to 
promote the blockade of VEGF pathway, intervening in neovascularization of the tumor 
and, consequently, in tumor growth, decreasing its size [49, 50]. It was approved by the 
food and drug administration (FDA) in 2009 for recurrent GBM. Two phase II multicenter 
and randomized CT were performed to evaluate the safety of bevacizumab with or with-
out irinotecan (a cytotoxic prodrug which inhibits DNA replication and activates apop-
totic cell death) in patients with recurrent GBM, where treatment-associated toxicity was 
documented in some of the patients [51]. For newly diagnosed GBM patients, this drug 
has been investigated together with standard therapy in comparative studies to assess the 
use of bevacizumab as first-line treatment. Two randomized double-blind placebo-control 
trials [52, 53] and one open-label single-arm phase II CT [54] showed that the addition 
of bevacizumab to standard therapy prolonged the progression-free survival (PFS), but 
did not improve OS. Additionally, serious adverse events related to bevacizumab were 
also reported in these trials. Thus, the efficacy of bevacizumab on quality of life of newly 
diagnosed GBM patients was not clearly specified and further well-designed CT should 
be performed. Other ongoing CT of bevacizumab agent in GBM treatment are present in 
Table 2. Inversely to bevacizumab, there are other mAbs agents that specifically target 
EGFR and/or EGFRvIII, which are the most common tumor-expressed targets explored in 
antibody therapy. EGFR is expressed in approximately 40% of GBM patients and 65% of 
them present EGFRvIII mutation [49]. These mAbs have the ability to blockade ligand bind-
ing or signaling through these receptors, interfering with tumor growth rates and inducing 
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Strategy Drug/antigen Other therapy Clinical phase 
(status)
Clinical trial ID
mAbs Bevacizumab — I/II (recruiting) NCT01811498
— II (not recruiting) NCT02157103
TMZ III (recruiting) NCT02761070
TMZ II (not recruiting) NCT01149850
Nimotuzumab RT plus TMZ III (completed) NCT00753246
RT plus TMZ II (completed) NCT03388372
Cetuximab RT plus TMZ I/II (recruiting) NCT02861898
ABT-414 RT plus TMZ I (completed) NCT01800695
RT plus TMZ III (recruiting) NCT02573324
TMZ or lomustine II (recruiting) NCT02343406
AMG595 — I (completed) NCT01475006
Immune 
checkpoint 
inhibitors
Nivolumab (anti-PD-1) RT and TMZ III (recruiting) NCT02617589
RT plus TMZ III (recruiting) NCT02667587
Pembrolizumab 
(anti-PD-L1)
— Pilot (recruiting) NCT02852655
RT plus TMZ I/II (not 
recruiting)
NCT02530502
Bevacizumab II (not recruiting) NCT02337491
RT plus TMZ; HSPPC-96 
vaccine
II (recruiting) NCT03018288
Durvalumab 
(anti-PD-L1)
Bevacizumab or RT II (not recruiting) NCT02336165
Avelumab (anti-PD-L1) RT plus TMZ II (recruiting) NCT03047473
Nivolumab (anti-PD-1) 
and ipilimumab 
(anti-CTLA-4)
TMZ I (not recruiting) NCT02311920
Bevacizumab III (not 
recruiting)
NCT02017717
Adoptive T-cell 
therapy
CMV-CTL TMZ I/II (recruiting) NCT02661282
CMV-ALT RT plus TMZ I (completed) NCT00693095
CAR T-cell 
therapy
IL-13Rα2 — I (recruiting) NCT02208362
— Pilot (completed) NCT00730613
EphA2 — I/II (completed) NCT02575261
HER2 CMV-CTL I (not recruiting) NCT01109095
— I/II (recruiting) NCT02713984
RT plus TMZ I (recruiting) NCT02442297
EGFRvIII Fludarabine and 
cyclophosphamide
Pilot (recruiting) NCT02844062
Fludarabine, 
cyclophosphamide and 
IL-2
I/II (recruiting) NCT01454596
— I (not recruiting) NCT02209376
RT plus TMZ I (recruiting) NCT02664363
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apoptosis, as well as providing a better sensitization of tumors to chemotherapeutic agents 
[48]. Examples of these mAbs are nimotuzumab and cetuximab, which are tested in clinical 
stage with early promising outcomes in the majority of the cases. More details about their 
CT are displayed in Table 2.
A recent and promising strategy using mAbs is based on antibody drug-conjugate (ADC), 
where mAbs are linked to cytotoxic molecules that specifically target tumor cells, promoting 
delivery of drugs or toxins. ABT-414 and AMG595 are two examples of ADCs that specifically 
target EGFRvIII and are under investigation for the treatment of GBM (Table 2) [49, 50].
3.2. Immune checkpoint inhibitors
Immune checkpoints are molecules that can attenuate the strength and duration of the normal 
activity of CTLs and are responsible for preventing autoimmunity and mitigating collateral 
tissue damage [5, 55, 56]. Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) is the most studied immune checkpoints molecules that pro-
vide immune resistance mechanisms at different levels and by different mechanisms, leading 
to inhibition of T-cell proliferation and cytokine production, consequently resulting in a non-
activation of T-cells [2, 56]. Both PD-1 and CTLA-4 are receptors expressed on the surface 
of T-cells [51]. PD-1 blocks T-cells at advanced stages of the immune response and interact 
with one of the PD-1 ligands expressed on the surface of tumor cells (such as PD-L1/B7.H1 or 
PD-L2/B7-DC), while CTLA-4 occurs early in T-cell immune response and binds to ligands 
expressed on the surface of APCs (such as B7.1/CD80 and B7.2/CD86) [2, 56].
Strategy Drug/antigen Other therapy Clinical phase 
(status)
Clinical trial ID
OVs HSV-1 M032 — I (recruiting) NCT02062827
DNX-2401 TMZ I (completed) NCT01956734
IFN-γ I (not recruiting) NCT02197169
— I (recruiting) NCT03178032
Pembrolizumab II (recruiting) NCT02798406
AdV-tK RT and valacyclovir II (completed) NCT00589875
RT and valacyclovir I (completed) NCT00751270
Reolysin RT and/or chemotherapy I (completed) NCT00528684
mAbs: monoclonal antibodies; TMZ: temozolomide; RT: radiotherapy; PD-1: programmed cell death protein 1; 
CTLA-4: cytotoxic T-lymphocyte-associated protein 4; HSPPC-96: heat-shock protein peptide complex 96; CMV-CTL: 
cytomegalovirus cytotoxic T lymphocytes; CMV-ALT: cytomegalovirus autologous lymphocyte transfer; CAR: chimeric 
antigen receptor; IL-13Rα2: interleukin-13 receptor alpha 2; HER2: human epidermal growth factor receptor 2; EphA2: 
erythropoietin-producing hepatocellular carcinoma 2; EGFRvIII: epidermal growth factor receptor variant III mutation; 
IL-2: interleukin-2; Ovs: oncolytic viruses; HSV: herpes simplex virus (HSV); IFN-γ: interferon gamma; AdV-tK: 
adenovirus mutant thymidine kinase.
Table 2. Representative CT of immunotherapeutic strategies in GBM treatment, including mAbs, immune checkpoint 
inhibitors, adoptive T-cell therapy, CAR T-cell therapy and OVs.
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A strategy based on the blockade of these inhibitory receptors and their ligands through the 
use of antibodies has been explored as a promising immunotherapeutic approach for diverse 
solid tumors, such as glioblastoma, inducing T-cell-mediated antitumor immunity [6]. PD-1 is 
expressed on activated T-cells, B-cells, DCs and macrophages and the expression of PD-L1 has 
been reported in glioma cell lines and tumor tissues, as well as in activated APCs in glioma 
patients, and its level of occurrence is associated with glioma grade [55]. Preclinical studies 
using antibodies to target PD-1/PD-L1 in animal glioma models showed encouraging results, 
especially in combination with radiotherapy [2, 57], which provided a strong support to proceed 
to clinical stage. Several CT are ongoing to evaluate the safety and efficacy of anti-PD-1/PD-L1 
human antibodies, namely nivolumab (anti-PD-1 antibody) and pembrolizumab (anti-PD-L1 
antibody), which have been tested alone or in combination with other agents in GBM patients. 
Some of these trials are in early phases, but two phase III trials are evaluating nivolumab 
and comparing it with standard therapy (NCT02617589 and NCT02667587). In a preclinical 
stage, the anti-CTLA-4 strategy has also demonstrated robust and effective response rates, 
with an increasing of long-term survival in 80% of treated mice [5]. Clinically, the safety and 
efficacy of nivolumab with or without ipilumumab, an anti-CTLA-4 human antibody, in GBM 
patients, are assessed in phase I and III trials (NCT02311920 and NCT02017717, respectively). 
This combinatorial PD-1 and CTLA-4 blockade demonstrated the most effective results. More 
information about immune checkpoint inhibitors trials is summarized in Table 2.
Despite their great impact on survival, this immunotherapeutic approach presents some limi-
tations, reflected by the immune-associated side effects experienced by some patients, such 
as dermatological, endocrinological, gastrointestinal, and hepatic toxicities, which have been 
reported like associated with the abnormal infiltration of stimulated CD4+–CD8+ T-cells into 
normal tissues with the concurrent elevation of levels of pro-inflammatory cytokines [2].
3.3. Chimeric antigen receptor (CAR) T-cell therapy
Adoptive T-cell therapy has also been widely applied in treatment of highly aggressive and 
advanced tumors, including GBM [58]. This therapy is based on direct T-cells activation and 
can be described in a simple way through the isolation of tumor-specific autologous T-cells 
and in vitro expansion followed by their injection into the patient, in order to improve anti-
tumor activity [5, 6]. As referred previously, CMV has been suggested as a potential GBM 
therapeutic target, due to the expression of its antigens in GBM cells, but not in surrounding 
healthy brain tissue. In a phase I CT for recurrent GBM patients, the feasibility and safety of 
a combinatorial therapy of autologous adoptively CMV-specific T-cell therapy and chemo-
therapy were demonstrated, highlighting the power of this antiviral therapy to improve GBM 
prognosis [59]. Other examples of CTs regarding CMV adoptive T-cell therapy are depicted 
in Table 2. However, it has been observed that this immunotherapeutic strategy is limited by 
the immunosuppressive tumor microenvironment, and the need of T-cells to recognize tumor 
antigens presented by the MHC class I [2, 60].
A novel type of adoptive T-cell therapy that has been proposed to overcome these shortcomings, 
is based on the transference of autologous T-cells genetically modified with CARs [5]. CARs are 
cell surface receptors selected to establish a high specificity with tumor cells and provide T-cell 
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activation through a mechanism where the antigen-binding region of a mAb is fused with the 
T-cell receptor (TCR) signaling domain CD3. They allow an antibody-like antigen recognition 
in a non-MHC-restricted pathway and a more effective T-cell penetration and persistence into 
the tumor microenvironment than mAbs [60, 61]. The implementation of CAR T-cell therapy in 
GBM treatment has demonstrated to be highly promising, where several GBM-specific antigens 
have been investigated as targets, such as (IL-13Rα2), human epidermal growth factor receptor 
2 (HER2), erythropoietin-producing hepatocellular carcinoma 2 (EphA2) and EGFRvIII [50, 61]. 
Preclinical studies that involve these targets are associated with positive outcomes, and all of 
them are also ongoing in a clinical stage [5]. A pilot study of intracranial delivery of CAR T-cells 
targeting IL-13Rα2 into the resection cavity of three patients with recurrent GBM (NCT00730613) 
provided preliminary results about its safety and feasibility, showing that the strategy was well-
tolerated without the emergence of serious side effects. Further, a transient antitumor activity 
was developed in two of the patients and the decrease of IL-13Rα2 expression within the tumor 
was confirmed in one patient [62]. Regarding the application of CAR T-cells therapy for EphA2 
positive malignant glioma patients, a phase I/II CT (NCT02575261) was completed, where the 
effectiveness, safety, and clinical response were evaluated, but the results have not yet been 
published. A phase I trial of CMV-specific CAR T-cells therapy targeting HER2 (NCT01109095), 
considered a more active strategy that reacts with the virus and tumor cells is also in progress 
to investigate its safety and efficacy in the treatment of patients with GBM. Several clinical trials 
exploring CAR T-cells targeting EGFRvIII in GBM are underway to test the safety and effective-
ness of this approach. More detailed information about these CAR T-cell clinical trials, as well 
as other examples, can be found in Table 2. Phase I/II clinical trials have provided early results 
of potential efficacy with an acceptable toxicity profile, but more efforts need to be carried out 
to assess the efficacy of the application of CAR T-cell therapy in GBM treatment. Despite the 
tolerable toxicity, cytokine release syndrome (CRS) is the most frequent adverse effect due to 
the extreme immune activation, especially evidenced in the case of intravenous administration. 
Furthermore, additional disadvantages are the high cost of the therapy and the possibility of 
expression of the target antigen on healthy tissues [61].
3.4. Oncolytic viruses (OVs)
Oncolytic virotherapy is another emerging immunotherapeutic strategy that has been investi-
gated in the treatment of GBM, evidencing promising results. OVs are replication-competent 
viral vectors used to induce effective antiviral and antitumor immune responses [2, 51]. They 
are able to selectively replicate in tumor cells through cell surface marker identification, induce 
tumor cell death, spread within the tumor and indirectly recruit immune cells to promote 
immune responses against themselves and infected and uninfected tumor cells [58, 63]. They 
can naturally occur or are genetically manipulated to specifically infect and destroy tumor 
cells overexpressing tumor antigens [50, 51]. Once all the tumor cells are eradicated, the excess 
of virus can be removed using an anti-viral medication [49]. Several OVs are under investiga-
tion for GBM targeting. Some of them have been tested at different stages of CTs, including 
herpes simplex virus (HSV), adenovirus (AdV), measles virus (MV), poliovirus (PV), reovirus, 
H1 parvovirus and Newcastle disease virus (NDV), after preclinical researches showing anti-
tumor activity, and many of the remaining OVs are in advanced preclinical stages [63].
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HSV is a neurotropic human pathogen that provides tumor selectivity with safety and the most 
intensively studied examples of genetically modified mutant HSV are G207 and HSV1716 [51]. 
Phase I and Ib trials performed to evaluate the safety of G207 inoculation into the brain resec-
tion cavity for recurrent GBM showed no treatment-related toxicity neither serious adverse 
effects, with no patients developing HSV encephalitis, and encouraging therapeutic efficacy 
was reported [2]. Another phase I trial that combines G207 oncolytic HSV therapy with 
radiotherapy also demonstrated safety and potential antitumor activity in the treatment of 
recurrent GBM patients [64]. HSV1716 is also reported in phase I trials, where no toxicity 
ascribed to HSV1716 was demonstrated [65, 66]. Another example of a genetically modified 
mutant HSV that has been investigated (HSV-1 M032) is presented in Table 2. Relatively to 
genetically engineered AdVs, which are non-enveloped virus with a double-stranded linear 
DNA genome, the most commonly investigated in GBM treatment are DNX-2401, ONYX-
015 and AdV-tK [2, 49–51]. In the case of DNX-2401, the tumor targeting is achieved and 
increased due to the presence of cyclic arginine/glycine/aspartic acid (cRGD) peptide that 
permits the attachment to host’s immune cells [50]. In a phase I trial of DNX-2401 oncolytic 
AdV, patients with recurrent high-grade glioma were subjected to an intratumoral injec-
tion in a dose escalation, demonstrating that this AdV is able to infect, replicate in and 
kill human glioma cells, without a harming toxicity profile. Furthermore, despite the early 
stage of the trial, a promising efficacy was expected, where 12% of the patients demonstrate 
durable complete therapeutic responses [67]. Other phase I CTs of DNX-2401 are displayed 
in Table 2. On the other hand, ONYX-015 oncolytic AdV was also tested in a phase I trial, 
through intracerebral injection of various doses in patients with recurrent glioma that was 
resected, where no serious related-treatment adverse events were identified, even at the 
highest administered dose [2]. For AdV-tK, an AdV mutant thymidine kinase, a randomized 
phase II trial (NCT00870181) was carried out with the parallel administration of ganciclovir, 
showing an improvement of PFS and OS in the treatment of patients with recurrent high 
grade glioma. Other CTs of AdV-tK are presented in Table 2. MV is an RNA virus and the 
genetically modified derivatives of MVs, such as modified Edmonston (MV-Edm) vaccine, 
have an affinity for cellular CD46 receptor abundantly expressed on tumor cells [2]. In addi-
tion, with the aim of facilitating in vivo monitoring of viral gene expression and replica-
tion, this MV has been engineered to express the human carcinoembryonic antigen (CEA; 
MV-Edm-CEA), which is expressed by various types of cancers, but not by gliomas [51]. 
However, MV-Edm-CEA has exhibited a great potential as an oncolytic therapy for GBM 
in preclinical studies. A phase I CTs with this MV (NCT00390299) was initiated to evaluate 
the MV-Edm-CEA-associated adverse effects and its best dose in patients with recurrent 
GBM, however, this study was recently suspended by reasons not yet reported. PV is an 
enterovirus that encompasses a protein capsid and RNA, expressing high-affinity for neo-
plastic cells and tropism to motor neurons [51]. A genetically recombinant polio/rhinovirus 
chimera, PVSRIPO, was developed to reduce the neurotoxicity frequently observed in cases 
of human poliomyelitis, avoiding neuvirulence tendency. This PV recognize the CD155 cell 
surface polio receptor, a tumor antigen widely expressed in tumor cells, including GBM [51, 
58]. A phase I trial is underway to evaluate the safety and the occurrence of potential antitu-
mor responses of intratumoral administration of PVSRIPO in patients with recurrent GBM 
(NCT01491893). Preliminary reported results of this clinical trial described that the infusion 
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of PVSRIPO was well-tolerated and revealed a promising efficacy, as well as provided a 
survival advantage when compared to historical control group of patients that was also 
analyzed [51]. Reovirus is a double-stranded RNA virus that is isolated from the respiratory 
and gastrointestinal tracts of humans. The safety of intratumoral administration in a dose-
escalation of this genetically unmodified OV was also assessed in a phase I trial in patients 
with recurrent GBM that received prior radiotherapy with or without chemotherapy [68]. 
More information about a phase I trial of reolysin, a genetically engineered reovirus, is 
depicted in Table 2.
The use of OVs has been shown through some CTs as a harmless strategy with promising 
results; however, no OV has yet been approved by the FDA for GBM [58]. On the other hand, 
their therapeutic efficacy needs to be thoroughly assessed and proven with convincing clini-
cal success in advanced phase trials. This task is hampered by the high genetic heterogeneity 
of GBM, and the ability of BBB to inhibit migration of OVs to the tumor site, thus compromis-
ing the success of the treatment [6].
4. Conclusions
The current, first line, GBM standard therapy has not provided the necessary and expected 
improvements in overall patient survival rates. Immunotherapy is being explored as an alter-
native strategy, revealing to be a promising field, associated with good outcomes and fewer 
adverse events.
The advances in technology, as well as in scientific knowledge regarding gene expression 
and signaling pathways analysis, have provided data to translate into new perspectives on 
personalized therapeutic approaches. In this context, immunotherapy has gained impor-
tance insofar as the identification of specific biomarkers in each patient could be useful for 
prognosis of personal immune responses. Several immunotherapeutic CTs are currently 
ongoing for GBM, predominantly using vaccines, and the preliminary results attained so 
far yielded satisfactory clinical responses associated with antitumor activity. However, 
some challenges have been reported, which are associated to finding therapeutic agents 
capable to penetrate the BBB, the identification of suitable, specific and immunogenic 
tumor antigens and appropriate pre- and post-therapeutic markers in order to develop 
immune-targeted agents. Other limitations comprise the reduced number of GBM patients 
skilled to incorporate particular clinical studies, and the insufficient understanding of the 
immune system as well as the GBM microenvironment. Given the molecular heterogeneity 
and immunosuppression that so well depict the GBM, combinatorial therapies targeting 
multiple pathways now become a need and so they have already been explored. A variety 
of regimens have been equated, combining immunotherapeutic strategies (vaccines, cell 
therapies, multiple checkpoint inhibitors, and antibodies) along with molecules target-
ing either tumor cells or their microenvironment, as well the current standard therapy. 
Consequently, more advanced CTs need to be underway to deeply explore the fundamen-
tal insights of these therapies. In addition, the discovery of new targets and mechanisms is 
essential in order to help widespread this field of research, and develop optimized thera-
peutic strategies for GBM.
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